All Stories

  1. Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine

    Article • OncoTargets and Therapy, April 2018, Dove Medical Press

    Dr Gennaro Riccio, Rolando Paciello